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 Introduction 
 3-Hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors (statins) were established in 1987 for treating 
hypercholesterolemia  [1] and are now one of the most 
widely used drugs in coronary artery disease (CAD). Sev-
eral randomized, placebo-controlled trials showed that 
statins can substantially reduce the incidence of clinical 
coronary disease in both primary and secondary preven-
tion  [2–5] . A 2004 meta-analysis of 97 randomized con-
trolled trials investigating different lipid-lowering inter-
ventions showed that statins are the only lipid-lowering 
agents that reduce overall mortality and strokes in pri-
mary and secondary prevention of CAD  [6] . The likely 
mechanisms of benefit are not solely attributed to the lip-
id-lowering effects of statins, but also to the variety of 
anti-inflammatory and antiproliferative effects, com-
monly described as pleiotropic effects  [7–11] .
 While the benefits of statin therapy in patients with 
stable CAD are clearly recognized, there have been con-
flicting results on whether early use of statins reduces 
myocardial infarction or overall mortality in the first 
months following acute coronary syndrome (ACS). The 
MIRACL (Myocardial Ischemia Reduction with Aggres-
sive Cholesterol Lowering) [12] and the PROVE IT 
(Pravastatin or Atorvastatin Evaluation and Infection 
Therapy) [13] trials both showed that high-dose atorva-
 Key Words 
 Acute coronary syndromes   Statin therapy   Presentation 
mode   AMIS project 
 Abstract 
 Objectives: The role of statin use in the treatment of acute 
coronary syndromes (ACS) is not clear. The aim of our study 
was to evaluate the role of statins in ACS.  Methods: Using 
data from the Acute Myocardial Infarction in Switzerland 
(AMIS Plus) Project, we compared the effects of chronic 
statin use, statin therapy after admission and no statin ther-
apy on presentation mode and outcomes in ACS.  Results: 
Available data from the period 2001–2006 including 11,603 
patients were analyzed. Major cardiac event rates and in-
hospital mortality were more common in statin-naive pa-
tients compared to patients who received statins.  Conclu-
sions: Our results support the importance of statin treatment 
in ACS. Chronic statin therapy seems to alter the initial pre-
sentation of ACS but it is questionable whether it provides 
an additional effect on early outcomes compared to the es-
tablishment of statin therapy after admission in statin-naive 
patients.  Copyright © 2007 S. Karger AG, Basel 
 Received: November 7, 2006 
 Accepted after revision: December 25, 2006 
 Published online: August 28, 2007 
 Prof. Dr. med. Paul Erne 
 Department of Cardiology 
 Kantonsspital Luzern 
 CH–6000 Luzern 16 (Switzerland) 
 Tel. +41 41 205 5106, Fax +41 41 205 2234, E-Mail paul.erne@ksl.ch 
 © 2007 S. Karger AG, Basel
0008–6312/08/1093–0156$24.50/0 
 Accessible online at:
www.karger.com/crd 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
5/
20
17
 1
0:
37
:3
1 
AM
 Statin Therapy in Acute Coronary 
Syndromes 
Cardiology 2008;109:156–162 157
statin (80 mg) when started within the first 10 days fol-
lowing ACS was superior to controls (placebo in the 
MIRACL study and 40 mg pravastatin in the PROVE IT 
trial) and reduced early cardiovascular morbidity. The A 
to Z trial  [14] which compared simvastatin (40 mg) for 1 
month followed by 80 mg thereafter to placebo found no 
difference in the primary outcome (composite of cardio-
vascular death, myocardial infarction, readmission for 
ACS, and stroke) during the first 4 months of follow-up. 
A recent meta-analysis of randomized controlled trials 
regarding statin initiation in ACS questioned the positive 
effect of these drugs on early outcomes such as death, 
myocardial infarction or stroke  [15] . Another meta-anal-
ysis showed that early, intensive statin therapy reduces 
death and cardiovascular events after 4 months of treat-
ment  [16] .
 Little is known about the effect of chronic statin treat-
ment on the presentation mode of ACS. In a recent case-
control study statin and   -blocker use was shown to sig-
nificantly alter the initial presentation of CAD  [17] . In 
that study statin use was associated with lower odds of 
presenting with an acute myocardial infarction than with 
stable angina. Another observational study showed that 
patients who were already taking statins when they pre-
sented to the hospital were less likely to have ST segment 
elevation myocardial infarction (STEMI)  [18] . 
 Using data from the Acute Myocardial Infarction in 
Switzerland (AMIS Plus), a large national registry of ACS, 
we analyzed the effect of statin therapy on presentation 
mode and outcomes in ACS.
 Methods 
 The AMIS Plus Registry 
 The AMIS Plus Project is a nationwide prospective registry of 
patients with ACS admitted to hospitals in Switzerland. The reg-
istry began in 1997, and patient recruitment has been ongoing 
since. Participating centers, ranging from community institu-
tions to large tertiary facilities, provide blinded data for each pa-
tient through a standardized Internet- or paper-based question-
naire. The details of the AMIS Plus Project have been published 
elsewhere  [19–21] .
 Patients 
 The AMIS Plus registry included all patients with ACS: acute 
myocardial infarction, defined by characteristic symptoms and/or 
ECG changes and enzyme rises (total creatine kinase or creatine 
kinase MB fraction) of at least twice the upper limit of normal, ACS 
with minimal necrosis (symptoms or ECG changes compatible 
with ACS and cardiac enzymes lower than twice the upper limit of 
normal range and positive troponins) and unstable angina (symp-
toms or ECG changes compatible with ACS and normal cardiac 
enzymes). Valid data since 2001 on pretreatment and early treat-
ment with statins were available and those data were analyzed. 
Baseline characteristics and outcomes are compared between pa-
tients on chronic statin therapy and who continued with the ther-
apy after admission (group A), patients without statin pretreat-
ment and in whom statin therapy was started after admission 
(group B), and patients without statin pretreatment who were not 
started on a statin when admitted (group C). Patients were also 
categorized as having ST segment elevation ACS (STEMI) or non-
ST elevation myocardial infarction (NSTEMI) based on initial 
ECG findings. Classification of ST segment elevation-ACS includ-
ed evidence of ACS as above and ST segment elevation and/or new 
left bundle branch block on the initial ECG. NSTEMI included pa-
tients with ischemic symptoms, ST segment depression or T wave 
abnormalities in the absence of ST elevation on the initial ECG. 
Major adverse cardiac events (MACE) were defined as a composed 
endpoint of reinfarction, stroke and/or in-hospital death. In March 
2005 the AMIS Plus Questionnaire was revised and more angio-
graphic parameters were added [e.g. vessel treated, left ventricular 
ejection fraction, thrombolysis in myocardial infarction (TIMI) 
flow at the end of percutaneous intervention (PCI)].
 Statistical Analyses 
 Data are presented as percentages of valid cases for discrete 
variables and as mean  8 SD and/or median for continuous vari-
ables. Differences in baseline characteristics were compared us-
ing t test and    2  test. A p value of  ! 0.05 was considered significant. 
User-defined missing values are treated as missing. Statistics for 
each table are based on all cases with valid data in the specified 
ranges for all variables in each table. Odds ratios (OR) with 95% 
of confidence interval for OR of in-hospital mortality were calcu-
lated using logistic regression models. The following factors were 
included in the multivariate analysis: statin treatment, age, gen-
der, history of CAD, hypertension, diabetes, dyslipidemia, smok-
ing, overweight, ST segment elevation, Killip class and use of PCI. 
SPSS software (Chicago, Ill., USA; Version 13.0) was used for all 
statistical analyses.
 Results 
 Baseline Characteristics  
 Of the 12,742 patients admitted for ACS and enrolled 
in the AMIS Plus registry from January 2001 through to 
March 2006, 11,603 patients (91.1%) were available for 
this analysis: 3,274 (28.2%) patients were on chronic 
statin treatment upon admission (group A) compared to 
8,329 subjects (71.8%) who were statin naive. In these 
statin-naive patients, statin therapy was started in 5,567 
patients (66.8%) after admission (group B), while 2,762 
(33.2%) never received a statin (group C).
 Baseline characteristics of the three groups are pre-
sented in  table 1 . Mean age was 66  8 12 years in group 
A, 63  8 13 years in group B and 70  8 14 years in group 
C. The proportion of males was similar in group A and B 
(75.8 vs. 74.8%) and lower in group C (65%).
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
5/
20
17
 1
0:
37
:3
1 
AM
 Cuculi et al.
 
Cardiology 2008;109:156–162158
 Presentation Mode, Complication and Outcome 
according to Statin Pretreatment 
 The proportion of STEMI was higher in statin-naive 
patients than in patients on chronic statin treatment (63 
vs. 46%, p  ! 0.001) ( fig. 1 ).
 Complications and outcome of ACS patients accord-
ing to statin pretreatment and statin start after admission 
are presented in  table 2 . The rate of occurrence of cardio-
genic shock was slightly higher in patients with chronic 
statin pretreatment (group A) compared to patients with-
out pretreatment but with statin start after admission 
(group B; 4.3 vs. 3.3%; p = 0.025). Patients without statin 
pretreatment and who were not started on a statin upon 
admission had a more than 2-fold higher rate of cardio-
genic shock (10.3%, compared with group A and B, p  ! 
0.001). Reinfarction was more common in patients of 
group C (2.3%) although not significantly different from 
reinfarction rates in group A (1.8%) and group B (1.8%;
p = 0.34). Stroke rate was more common in group C 
(1.2%) than in group A (0.5%) and B (0.7%; p = 0.009). 
Need for respiratory support (intubation) was signifi-
cantly different between the three groups: group A (3.6%), 
group B (2.5%) and group C (6.2%; p  ! 0.001).
 The overall MACE rates were 6.5% in group A, 5.6% 
in group B and 15.3% in group C. The difference between 
group A and B was not significant, while the MACE rates 
of group C were significantly higher than those of group 
A and B (p  ! 0.001).  Table 3 shows independent predic-
tors for MACE in ACS patients. Immediate statin therapy 
(in statin-naive patients), age, history of diabetes, history 
of dyslipidemia, ST segment elevation, Killip class II–IV 
and use of primary PCI were significant predictors of 
MACE.
 The unadjusted OR for in-hospital mortality for 
chronic statin therapy was 0.32 (95% CI 0.26–0.39; p  ! 
0.001) and for statin therapy after admission (in statin-
naive patients) OR was 0.25 (95% CI 0.21–0.30; p  ! 
0.001). After adjustment for all variables the OR for 
chronic statin therapy was no longer significant (OR 
0.76, CI 95% 0.53–1.08; p = 0.125), but statin therapy af-
ter admission (in statin-naive patients) remained signif-
icant even after adjustment for age, gender, history of 
CAD, hypertension, diabetes, dyslipidemia, smoking, 
overweight, ST segment elevation, Killip class and pri-
mary PCI.
 Complication and Outcome in Various Risk Groups  
 MACE rates in various risk categories (age  1 70, dia-
betes, renal failure) are presented in  figure 2 . Group C 
had the highest MACE rates independently of the risk 
category (p  ! 0.001 for all comparisons of group C with 
group A and B). In group C the MACE rates were highest 
in patients with renal disease (29.4%), diabetes (23.1%) 
and patients older than 70 years (21.7%). The MACE 
Group A
(n = 3,274)
Group B
(n = 5,567)
Group C
(n = 2,762)
Mean age (8SD), years 66812 63813 70814 
Males, % 75.8 74.8 65.0
Known history of
CAD, % 66.4 25.0 32.7
Hypertension, % 71.6 51.2 57.5
Diabetes, % 28.5 15.6 20.0
Dyslipidemia, % 88.8 57.2 41.1
Current smokers, % 32.2 42.8 33.4
Overweight (BMI >25), % 69.3 64.9 55.9
Table 1. Baseline characteristics of the 
study population
Proportion of STEMI in patients with and without 
chronic statin use
STATIN
NO STATIN
70%60%50%40%30%20%10%0%
 Fig. 1. Presentation mode of ACS according to statin pretreatment 
(n = 11,571). 
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rates were comparable in group A and B for patients 
younger than 70 years (3.6 vs. 3.0%), patients older than 
70 years (10.7 vs. 11.0%), patients with diabetes (9.0 vs. 
8.4%) and without diabetes (5.2 vs. 4.8%), and also for 
patients with (15.0 vs. 17.2%) and without renal disease 
(5.5 vs. 5.0%). 
 TIMI Flow according to Statin Treatment 
 TIMI flow rates at the end of the PCI were available for 
1,432 patients and are shown in  table 4 . TIMI III flow 
rates were higher in group A and B compared to group C 
but this did not reach statistical significance.
 Discussion 
 In our population of ACS patients the proportion of 
STEMI was 61% in statin-naive patients but only 46% in 
patients already on chronic statin therapy. Our observa-
tion that statin therapy indeed has an impact on the pre-
sentation mode of ACS (STEMI vs. NSTEMI/unstable 
angina) is consistent with the results of the GRACE 
(Global Registry of Acute Coronary Events) register  [18] 
where patients already taking statins were less likely to 
have STEMI on admission. Our analysis is also in accor-
dance with the results of Go et al. [17] who recently re-
Group A
(n = 3,274)
Group B
(n = 5,567)
Group C
(n = 2,762)
Intervention
Primary percutaneous intervention, % 48.2 56.7 36.1
Thrombolysis, % 6.3 10.8 10.4
Complication
Cardiogenic shock, % 4.3 3.3 10.3
Reinfarction, % 1.8 1.8 2.3
Cerebrovascular incident, % 0.5 0.7 1.2
Outcome
Major adverse cardiac event, % 6.5 5.6 15.3
In-hospital mortality, % 4.5 3.6 12.8
Table 2. Interventions, complications and 
outcome according to statin treatment
Table 3. Independent predictors for MACE in ACS patients
OR 95% CI Signi-
ficance
Chronic statin therapy (group A) 0.83 0.61–1.12 0.226
Immediate statin therapy (group B) 0.77 0.59–0.99 0.047
Age (per year) 1.05 1.04–1.06 <0.001
Gender 1.03 0.83–1.29 0.769
Diabetes 1.58 1.25–1.99 <0.001
Hypertension 0.88 0.71–1.11 0.285
Dyslipidemia 0.75 0.60–0.94 0.014
Smoking 1.13 0.88–1.45 0.322
History of CAD 1.13 0.91–1.42 0.275
Overweight (BMI >25) 0.84 0.68–1.03 0.095
ST segment elevation 1.39 1.11–1.72 0.003
Killip class II 2.30 1.81–2.93 <0.001
Killip class III 3.40 2.36–4.90 <0.001
Killip class IV 9.69 6.15–15.3 <0.001
PCI primary 0.68 0.54–0.87 0.002
Group A
Group B
Group C0%
5%
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 Fig. 2. MACE rates in various risk populations (n = 11,603). 
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ported that patients on statin and   -blocker therapy 
 present with stable angina rather than acute myocardial 
infarction. While the benefit of statin therapy on presen-
tation mode of ACS is plausible to explain (e.g. plaque 
stabilization), absolute proof that statins can really alter 
the mode of presentation of CAD still has to be obtained 
in a prospective trial. If confirmed, the findings could 
have a substantial impact on future patient care because 
NSTEMI and unstable angina are associated with a better 
prognosis than STEMI.
 Patients on chronic statin therapy and patients who 
were started on statins after admission had similar rates 
of reinfarction, cerebrovascular incidents and in-hospital 
mortality. Cardiogenic shock was slightly less common 
in group B (3.3%) compared to group A (4.3%) and mark-
edly high in group C (10.3%). The rate of major cardiac 
events was 6.5% for the group with chronic statin therapy 
and 5.6% for the group with in-hospital statin start. Pa-
tients who never received statins had excessively high 
rates of complications, e.g. cardiogenic shock (10.3%) and 
in-hospital mortality (12.8%). The MACE rate in this 
group of patients was very high (15.3%). MACE rates were 
consistently higher in group C even when different risk 
populations were compared ( 1 70 years,  ! 70 years, pa-
tients with and without diabetes and patients with and 
without renal disease). Patients in group B had signifi-
cantly lower (34%, p = 0.0006) in-hospital mortality than 
patients in group C. Patients in group A also had lower 
in-hospital mortality when compared to group C (OR 
0.76) but this did not reach statistical significance (p = 
0.125).
 The clearly better outcomes and lower complication 
rates of statin-pretreated patients were also observed in 
the GRACE  [18] and PRISM (Platelet Receptor Inhibition 
in Ischemic  Syndrome Management)  [22] studies. How-
ever, in both these studies the withdrawal of previous 
statin therapy resulted in worse outcomes. Interestingly, 
in our study better outcomes were observed in patients 
who were started on statins upon admission compared to 
patients already on chronic statin therapy and who con-
tinued with the therapy while hospitalized; patients with 
statin start after admission had lower in-hospital mortal-
ity and lower rates of cardiogenic shock. Our analysis in-
cluded the time period 2001–2006 and patients who were 
started on statin upon admission most likely received 
high-dose therapy, since both the MIRACL  [12] and the 
PROVE IT  [13] study (published in 2001 and 2004, re-
spectively) reported benefits of high-dose statin (i.e. 80 
mg of atorvastatin) therapy in patients with ACS. The fact 
that group A (compared to group B) included patients 
who were older and had a higher prevalence of diabetes, 
CAD, dyslipidemia and hypertension might also have in-
fluenced their worse outcome.
 Our study suggests that in ACS, chronic statin therapy 
might not have any additional effects on early outcomes 
over the establishment of statin therapy after admission. 
 The benefit of statin therapy seems to be accentuated 
in high-risk populations, such as older patients or those 
with diabetes or renal function impairment, as shown in 
 figure 2 . In our study patients in group C had a mean age 
of 70 years, being older than patients in group A (66 years) 
and group B (63 years). This fact suggests that, paradoxi-
cally, an effective and well-tolerated therapy is being 
withheld from older people, who are known to have a 
worse prognosis. However, more patients in group C 
needed respiratory support compared to groups A and B, 
which might partly explain the reason for statin with-
drawal in this group of patients.
 TIMI-III flow rates were higher in patients receiving 
statins but failed to show statistical significance. Recent-
ly, Iwakura et al. [23] reported that chronic pretreatment 
with statins is associated with the reduction of the no-re-
flow phenomenon in patients with reperfused acute myo-
cardial infarction.
 Study Limitations 
 Despite the prospective and multicenter character of 
our study one has to keep in mind that we present data 
from a registry and not a randomized controlled trial. 
Neither the dose of statins nor the time point at which 
statin therapy was started was defined.
 There were noticeable baseline differences in several 
important prognostic factors between our primary com-
parison groups. Although we attempted to control for the 
effects of potential confounding factors, it is conceivable 
Table 4. TIMI flow rates (in %) after PCI in different statin 
groups
TIMI flow
0 I II III
Group A (n = 457) 3.9 0.9 5.7 89.5
Group B (n = 836) 1.9 1.2 7.4 89.5
Group C (n = 139) 4.3 2.2 6.5 87.1
n.s. n.s. n.s. n.s.
n.s. = No significant differences between the groups.
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that differences in other unmeasured factors may have 
influenced our study findings. The results should there-
fore be interpreted with caution.
 Conclusions 
 Our findings provide additional evidence for the im-
portance of statin therapy in the treatment of ACS. 
Chronic statin therapy seems to alter the initial presenta-
tion of ACS but it is questionable whether there is an ad-
ditional effect on early outcomes compared to the estab-
lishment of statin therapy after admission in statin-naive 
patients. The benefit of statin therapy is accentuated in 
high-risk populations such as the elderly, diabetics or pa-
tients with renal failure. Despite the fact that bias due to 
group differences cannot be excluded and that we present 
data from a registry, not data from a randomized con-
trolled trial, our results favor the early establishment of 
statin therapy in ACS; statin therapy achieves a remark-
able reduction in mortality and this benefit is consistent 
in various risk groups.
 Appendix 1 
 Steering Committee 
 P. Erne, President, Lucerne; F.W. Amman, Zürich; O. Bertel, 
Zürich; E. Camenzind, Geneva; F. Eberli, Zürich; M. Essig, Zwei-
simmen, J.-M. Gaspoz, Geneva; F. Gutzwiller, Zürich; P. Hun-
ziker, Basel; M. Maggiorini, Zürich; B. Quartenoud, Fribourg; H. 
Rickli, St. Gallen; J.-C. Stauffer, Lausanne; P. Urban, Geneva; S. 
Windecker, Bern.
 AMIS Plus Participants 
 The following hospitals participated from 1997 to 2006 in the 
AMIS registry on which this report is based (in alphabetical or-
der): Altdorf, Kantonsspital Altdorf: Dr. R. Simon; Altstätten, 
Kantonales Spital Altstätten: Dr. P.-J. Hangartner/Dr. M. Rhyner; 
Baden, Kantonsspital Baden: Dr. M. Neuhaus; Basel, Kantonsspi-
tal Basel: PD Dr. P. Hunziker; Basel, St. Claraspital: Dr. C. Grädel; 
Bern, Inselspital: Prof. B. Meier/PD Dr. S. Windecker; Biel, Spi-
talzentrum Biel: Dr. H. Schläpfer; Brig-Glis, Oberwalliser Kreis-
spital: Dr. D. Evéquoz; Bülach, Spital Bülach: Dr. R. Pampaluchi/
Dr. A. Ciurea-Löchel/Dr. M. Kruhl; Chur, Rätisches Kantons- 
und Regionalspital Chur: Dr. P. Müller; Chur, Kreuzspital: Dr. V. 
Wüscher/Dr. R. Jecker; Davos Platz, Spital Davos: Dr. G. Nieder-
maier; Dornach, Spital Dornach: Dr. A. Koelz; Flawil, Kantonales 
Spital Flawil: Dr. T. Langenegger; Frauenfeld, Kantonsspital 
Frauenfeld: Dr. H.-P. Schmid; Fribourg, Hôpital cantonal de Fri-
bourg: Dr. B. Quartenoud; Frutigen, Spital Frutigen: Dr. S. Moser/
Dr. Kuengolt Bietenhard; Genève, Hôpitaux universitaires de Ge-
nève (HUG): Dr. J.-M. Gaspoz; Glarus, Kantonsspital Glarus: Dr. 
W. Wojtyna; Grenchen, Spital Grenchen: Dr. P. Schlup/Dr. A. 
Oestmann; Grosshöchstetten, Bezirksspital Grosshöchstetten: 
Dr. C. Simonin; Heiden, Kantonales Spital Heiden: Dr. R. Wald-
burger; Herisau, Kantonales Spital Herisau: Dr. P. Staub/Dr. M. 
Schmidli; Interlaken, Spital Interlaken: Dr. P. Sula; Jegenstorf, 
Spital Jegenstorf: Dr. H. Marty; Kreuzlingen, Herz-Neuro-
Zentrum Bodensee: Dr. K. Weber; La Chaux-de-Fonds, Hôpital 
La Chaux-de-Fonds: Dr. H. Zender; Lachen, Regionalspital 
Lachen: Dr. I. Poepping/Dr. C. Steffen; Langnau im Emmental, 
Regionalspital Emmental: Dr. J. Sollberger; Lugano, Cardiocen-
tro Ticino: Dr. G. Pedrazzini; Luzern, Kantonsspital Luzern: Prof. 
P. Erne; Männedorf, Kreisspital Männedorf: Dr. J. von Meyen-
burg/Dr. T. Luterbacher; Martigny, Hôpital régional de Martigny: 
Dr. B. Jordan; Mendrisio, Ospedale regionale di Mendrisio: Dr. A. 
Pagnamenta; Meyrin, Hôpital de la Tour: PD Dr. P. Urban; Mon-
they, Hôpital du Chablais: Dr. P. Feraud; Montreux, Hôpital de 
Zone: Dr. E. Beretta; Moutier, Hôpital du Jura bernois: Dr. C. 
Stettler; Münsingen, Regionales Spital Zentrum Münsingen: Dr. 
F. Repond; Münsterlingen, Kantonsspital Münsterlingen: Dr. F. 
Widmer; Muri, Kreisspital für das Freiamt: Dr. A. Spillmann/Dr. 
F. Scheibe/Dr. K. Rudaz-Schwaller; Nyon, Group. Hosp. Ouest 
lémanique: Dr. R. Polikar; Rheinfelden, Gesundheitszentrum 
Fricktal Regionalspital Rheinfelden: Dr. H.-U. Iselin; Rorschach, 
Kantonales Spital Rorschach: Dr. M. Pfister; Samedan, Spital 
Oberengadin: Dr. P. Egger; Sarnen, Kantonsspital Obwalden: Dr. 
T. Kaeslin; Schaffhausen, Kantonsspital Schaffhausen: Dr. R. 
Frey; Schlieren, Spital Limmattal: Dr. B. Risti/Dr. V. Stojanovic/
Dr. T. Herren; Schwyz, Spital Schwyz: Dr. P. Eichhorn; Scuol, Os-
pidal d’Engiadina Bassa: Dr. G. Flury/Dr. C. Neumeier; Solo-
thurn, Bürgerspital Solothurn: Dr. P. Hilti; St. Gallen, Kantons-
spital St. Gallen: Dr. W. Angehrn/Dr. H. Rickli; Thun, Spital 
Thun: Dr. U. Stoller; Thusis, Krankenhaus Thusis: Dr. U.-P. Ve-
ragut; Uster, Spital Uster: Dr. D. Maurer/PD Dr. J. Muntwyler; 
Uznach, Kantonales Spital Uznach: Dr. A. Weber; Wädenswil, 
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